GKIM
VRNA

GW&K Investment Management’s Verona Pharma VRNA Stock Holding History

GW&K Investment Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-193,782
Closed -$18.3M – 1015
2025
Q2 		$18.3M Sell
193,782
-330
-0.2% -$24.4K 0.16% 209
2025
Q1 		$12.3M Sell
194,112
-38,240
-16% -$2.29M 0.11% 242
2024
Q4 		$10.8M Buy
+232,352
New +$8.72M 0.09% 255

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GW&K Investment Management's VRNA Position: Q3 2025 in Review

GW&K Investment Management sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 193,782 shares — an estimated $18.3M sold.

GW&K Investment Management first reported a position in VRNA in Q4 2024 and held it in 3 quarters. The position peaked at $18.3M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • GW&K Investment Management reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • GW&K Investment Management sold 193,782 Verona Pharma shares in Q3 2025, an estimated $18.3M.
  • GW&K Investment Management first reported a position in Verona Pharma in Q4 2024 and held it in 3 quarters.
  • GW&K Investment Management's Verona Pharma position peaked at $18.3M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on GW&K Investment Management's 13F filing for Q3 2025, filed 12 Nov 2025.